98%
921
2 minutes
20
Objectives: To analyse clinical features and biomarkers associated with primary heart involvement (pHI) confirmed at cardiac magnetic resonance (CMR) in a monocentric cohort of SSc patients.
Methods: A retrospective study. SSc patients who underwent CMR for clinically suspected pHI were identified. SSc-pHI at CMR was defined by the presence of at least one abnormality among: non-ischaemic late gadolinium enhancement (LGE), myocardial oedema (STIR), increased extracellular volume (ECV), native T1 or T2-mapping. Clinical, laboratory and instrumental features were compared between pHI-SSc and non-pHI-SSc patients, and between CMR-positive and CMR-negative patients.
Results: 259 SSc patients (females 89.6%; median age 49 [39-61] years) were included. CMR was performed in 56 (21%) and pHI detected in 37 patients (14%). At univariate analysis, age at SSc onset, diffuse cutaneous subset, increased inflammatory markers and cardiac enzymes, interstitial lung disease (ILD) and myositis were significantly associated with SSc-pHI at CMR; an inverse correlation emerged with anti-centromere antibodies, VEDOSS and female gender. At multivariate analysis, increased troponin T(TnT) [OR 14.108, CI 2.772-71.808, P = 0.014], CRP [OR 11.237, CI 2.265-55.763, P = 0.0031] and the presence of ILD [OR 6.275, CI 1.240-31.763, P = 0.0264] were significantly associated with a positive CMR for SSc-pHI. Considering the 56 patients who underwent CMR, arrhythmias at 24 h-ECG-Holter were associated at univariate analysis to the presence of SSc-pHI at CMR [OR 3.75, CI 1.041-13.5, P = 0.04].
Conclusion: This retrospective analysis identified biomarkers and disease features associated with SSc-pHI confirmed at CMR. Our preliminary data suggest that increased serum levels of TnT and CRP, as well as the presence of ILD and arrhythmias might be considered as red flags suggesting to promptly proceed with a comprehensive cardiac evaluation, including CMR, to diagnose SSc-pHI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keaf234 | DOI Listing |
Rheumatology (Oxford)
September 2025
Unit of Immunology, Rheumatology, Allergy and Rare diseases-Scleroderma Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Objectives: To analyse clinical features and biomarkers associated with primary heart involvement (pHI) confirmed at cardiac magnetic resonance (CMR) in a monocentric cohort of SSc patients.
Methods: A retrospective study. SSc patients who underwent CMR for clinically suspected pHI were identified.
Semin Arthritis Rheum
April 2025
Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Background: Primary heart involvement (pHI) is frequent in systemic sclerosis (SSc), and is associated with a poor prognosis. Therapeutic strategies to treat SSc-pHI are not yet defined.
Objectives: To evaluate the efficacy of immunosuppressive therapy on cardiac magnetic resonance (CMR) features in patients with CMR-proven SSc-pHI.
Curr Opin Rheumatol
January 2024
Purpose Of Review: In systemic sclerosis (SSc) primary heart involvement (pHI) is frequent, even though often unrecognized due to its occult nature and to the lack of a specific diagnostic algorithm. The purpose of this review is to report the state of the art of the evidence in the current literature, as well as the overall diagnostic modalities and therapeutic strategies for primary heart involvement in SSc.
Recent Findings: SSc-pHI is defined by the presence of cardiac abnormalities that are predominantly attributable to SSc rather than other causes and/or complications; it may be sub-clinical and must be confirmed through diagnostic investigations.
RMD Open
October 2021
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, West Yorkshire, UK
Objectives: To explore the prognostic value of subclinical cardiovascular (CV) imaging measures and serum cardiac biomarkers in systemic sclerosis (SSc) for the development of CV outcomes of primary heart involvement (pHI).
Methods: Patients with SSc with no clinical SSc-pHI and no history of heart disease underwent cardiovascular magnetic resonance (CMR) imaging, and measurement of serum high-sensitivity-troponin I (hs-TnI) and N-terminal-pro-brain natriuretic peptide (NT-proBNP). Follow-up clinical and CV outcome data were recorded.